Recent Updates
Recently added Catalysts
CNTA Positive Sentiment Score: 70/100

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Key Takeaway: Centessa Pharmaceuticals plc (Nasdaq: CNTA) has announced its participation in two upcoming investor conferences: the Jefferies 2025 Global Healthcare Conference and the Goldman Sachs 46th Annual Global Healthcare Conference. Management team members will take part in fireside chats during both events. This participation highlights the company's commitment to engaging with investors and discussing its innovative therapies, including those related to excessive daytime sleepiness and immuno-oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Centessa Pharmaceuticals is actively participating in notable investor conferences, indicating engagement with the investment community.
  • The company's focus on developing transformational medicines offers promise in addressing multiple health issues.

Full Press Release Details

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Event: Jefferies 2025 Global Healthcare Conference
Fireside Chat: 11:40 AM ET
Event: Goldman Sachs 46th Annual Global Healthcare Conference
Fireside Chat: 9:20 AM ET
Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders. We also have an early-stage immuno-oncology program focused on our novel LockBody® technology platform. For more information, visit www.centessa.com, which does not form part of this release.
Kristen K. Sheppard, Esq.
SVP of Investor Relations

Frequently Asked Questions

What conferences will Centessa Pharmaceuticals attend?

Centessa Pharmaceuticals will participate in the Jefferies 2025 Global Healthcare Conference and the Goldman Sachs 46th Annual Global Healthcare Conference.

When is the Jefferies 2025 Healthcare Conference?

The Jefferies 2025 Global Healthcare Conference is scheduled for 11:40 AM ET.

How can I access the event webcasts?

Live webcasts and archived recordings can be accessed under the 'Events and Publications' tab on their investor relations website.

What is the focus of Centessa Pharmaceuticals' research?

Centessa Pharmaceuticals focuses on developing therapies for excessive daytime sleepiness and has an early-stage immuno-oncology program.

Who can be contacted for investor relations at Centessa?

Kristen K. Sheppard, Esq. is the SVP of Investor Relations, available at investors@centessa.com.

Last updated: May 19, 2025